TSE:4523Pharmaceuticals
Evaluating Eisai (TSE:4523) After New CTAD Alzheimer’s Data and Pipeline Updates
Eisai (TSE:4523) just put its Alzheimer’s program back in the spotlight at the CTAD conference, with fresh lecanemab and etalanetug data that sharpen the long term commercial picture around its neurology pipeline.
See our latest analysis for Eisai.
Those CTAD updates land after a choppy stretch for investors, with the 1 year total shareholder return at 10.27% but a 3 year total shareholder return still deeply negative, so near term momentum looks tentative while the long term rebuilds.
If...